Synthorx is a biotechnology company using synthetic biology to synthesize solutions for the discovery and development of novel therapeutics, diagnostics and vaccines. With the revolutionary advancement of synthetic nucleotides that can be maintained and replicated by a single-cell organism, Synthorx is exploring the natural and evolution-directed technologies to improve drug discovery. Using synthetic nucleotides to expand the genetic alphabet, Synthorx is developing novel proteins, RNA and DNA for medical applications. The company was founded by Avalon Ventures based on important discoveries in Dr. Floyd Romesberg's lab at The Scripps Research Institute in La Jolla, CA.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/08/14 | undisclosed |
Avalon Ventures Correlation Ventures | undisclosed | |
| 07/20/16 | $10,000,000 | Series B |
Avalon Ventures Correlation Ventures RA Capital Management | undisclosed |
| 04/30/18 | $63,000,000 | Series C |
Avalon Ventures Correlation Ventures Medicxi OrbiMed Advisors  Osage University Partners RA Capital | undisclosed |
